W-INITIATIVE
Norway’s best tennis player and superstar Casper Ruud (23) is the new global ambassador for the Norwegian humanitarian foundation W Initiative. The agreement involves a close partnership over the next three years.
W Initiative was established in 2021 by SalMar heir Gustav Magnar Witzoe (29), to support humanitarian activities that improve the quality of life for children and young people around the world.
“I am proud to promote W Initiative on an international arena. I can think of nothing more meaningful than to help children and young people have a better live, better health and more equal opportunities, which also includes games and sports,” says Casper Ruud, who is currently competing in the French Open Grand Slam tournament.
Long-term partnership
As ambassador, Casper Ruud will be promoting the foundation and making it more visible to an international audience. This includes wearing the W Initiative logo on his clothing, talking about the foundation’s work during interviews, in social media and on his own website, as well as participating in various events organised by the foundation. The goal for the W Initiative is to be more visible and, consequently, receive information about and access to new projects around the world that it can support.
“The foundation actively searches for projects around the world that align with key sustainability goals. Having Casper Ruud as an ambassador will open more doors and we can reach international audiences in a completely different way,” explains Managing Director of the foundation Eirik Boe Sletten.
Gustav Magnar Witzoe created W Initiative in 2021 and it is Witzoe’s company Forward Project that is funding the partnership with Casper Ruud, which starts on 1 June and lasts until the end of 2024. W Initiative will then have the preferential right to extend the partnership for another two years.
The right man
“When I first met Casper, it was immediately clear that he was the right ambassador for the foundation – not only because he is one of the world’s best athletes who plays on the world’s premiere arenas, but also because he is simply a great guy who shares the foundation’s values and views. His contribution comes at an important time in the evolution of the foundation. If this partnership can also contribute positively to his own development as Norway’s best tennis player, that’s fantastic,” says Witzoe.
Witzoe comes from a small rural Island off the west coast of Norway with a population of just over 4000. His father pioneered the fish farming industry, in time becoming one of the world’s most successful in the industry, with his company SalMar.
W Initiative aims to grow through effective management and expansion to make increasingly meaningful contributions.
“Our first project in Uganda, which is being carried out together with Right To Play, contributes to better water and sanitary conditions, in addition to games and sports for children in three districts in the country. We have also joined a new project in Fiji headed by FijiStiftelsen. Thanks to the support of the W Initiative, FijiStiftelsen will be building two evacuation centres that will be used daily as a classroom and multipurpose room for children, as well as give women the opportunity to create their own workplace,” explains Boe Sletten.
Download pictures here: Pictures
More info here: https://www.w-initiative.com/en
W Initiative facts and figures
W Initiative is a newly established humanitarian foundation that aims to improve the quality of life of children and young people. The projects supported by the foundation may be in Norway or elsewhere but must always be grounded in UN Sustainable Development Goals 3, 4, 5, 6 or 10. The projects must have a focus on increased competence, better health, and more equal opportunities. Gustav Magnar Witzoe has donated NOK 110 million to the foundation through his family-owned company, of which NOK 100 million is earmarked for the foundation’s founding capital to enable increasingly meaningful contributions through effective management and expansion. The foundation will actively seek out projects that align with its vision and purpose and it will not be possible to apply for funding from the foundation. The foundation wishes to work together with well-established organisations. An annual report will be published on status and progress based on the foundation’s objectives.
Management board
Witzoe is the son of SalMar founder Gustav Witzoe and is currently the majority shareholder of the parent company Kvarv AS. The management board also includes NTNU professor Heri Ramampiaro, associate attorney Kristina Jorgensen, chief physician Elisabeth Vesterbekkmo and civil engineer Magnus Witzoe. All board members have a different background, but with a strong affiliation with Trondelag.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
